Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 4:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: HCTZ + Amlodipine Clear all
Withdrawn Phase 4 Interventional

Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics

NCT00994253
View directory record Official record
Conditions
Hypertension, Diabetes Type 2
Interventions
Aliskiren, Hydrochlorothiazide
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 1, 2017 · Synced Sep 26, 2026, 4:53 AM EDT
Completed Phase 4 Interventional Results available

Valsartan Intensified Primary Care Reduction of Blood Pressure Study

NCT00902304
View directory record Official record
Conditions
Hypertension
Interventions
Valsartan and hydrochlorothiazide (HCTZ) - monotherapy, Valsartan and amlodipine, Usual care, Valsartan, Valsartan and hydrochlorothiazide (HCTZ) - combination arm
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Sep 26, 2026, 4:53 AM EDT
Completed Phase 4 Interventional

Efficacy of Valsartan/Hydrochlorothiazide Versus Amlodipine and Hydrochlorothiazide in Patients Hypertension

NCT00425997
View directory record Official record
Conditions
Hypertension
Interventions
Valsartan/HCTZ, amlodipine, HCTZ
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 26, 2026, 4:53 AM EDT
Completed Phase 4 Interventional

Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker

NCT00185120
View directory record Official record
Conditions
Hypertension
Interventions
Olmesartan medoxomil, Hydroclorothiazide, Benazepril, Amlodipine
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
20
States / cities
Mobile, Alabama • Long Beach, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2012 · Synced Sep 26, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 26, 2026, 4:53 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome

NCT01432106
View directory record Official record
Conditions
Hypertension, Metabolic Syndrome
Interventions
Aliskerin/Valsartan and Rampiril
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 17, 2013 · Synced Sep 26, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

CAndesartan vs LIsinopril Effects on the BRain

NCT01984164
View directory record Official record
Conditions
Hypertension, Mild Cognitive Impairment
Interventions
Candesartan, Lisinopril
Drug
Lead sponsor
Emory University
Other
Eligibility
55 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 26, 2026, 4:53 AM EDT
Completed Phase 3 Interventional

A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine

NCT00294710
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 80 Years
Enrollment
976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Sep 26, 2026, 4:53 AM EDT
Withdrawn Not applicable Interventional

The Pleiotropic Effects of Atorvastatin When Combined With Common Antihypertenisve Medications.

NCT00656331
View directory record Official record
Conditions
Hypertension
Interventions
Amlodipine and Hydrocholorothiazide
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Sep 26, 2026, 4:53 AM EDT
Completed Phase 4 Interventional Results available

Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults

NCT00439738
View directory record Official record
Conditions
Hypertension
Interventions
HCTZ + Amlodipine, Valsartan/HCTZ
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
5
States / cities
Muscle Shoals, Alabama • Westlake Village, California • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 26, 2026, 4:53 AM EDT
Completed Early Phase 1 Interventional

N-of-1 Trials for Blood Pressure Medications in Adults

NCT02744456
View directory record Official record
Conditions
Hypertension, High Blood Pressure
Interventions
Losartan, Amlodipine, Hydrochlorothiazide
Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 26, 2026, 4:53 AM EDT
Completed Not applicable Interventional

Renin Profiling in Selection of Initial Antihypertensive Drug

NCT00834600
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan, hydrochlorothiazide, amlodipine, hydrochlorothiazide (HCTZ) or olmesartan
Drug
Lead sponsor
The Louis & Rachel Rudin Foundation
Other
Eligibility
40 Years to 85 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
5
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Sep 26, 2026, 4:53 AM EDT
Completed Phase 4 Interventional Results available

Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension

NCT00931710
View directory record Official record
Conditions
Stage 2 Systolic Hypertension
Interventions
valsartan, amlodipine, HCTZ, Losartan, HCTZ followed by valsartan, amlodipine, HCTZ
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 6, 2011 · Synced Sep 26, 2026, 4:53 AM EDT
Completed Phase 4 Interventional Results available

A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure

NCT00791258
View directory record Official record
Conditions
Hypertension
Interventions
amlodipine and olmesartan medoxomil tablets, hydrochlorothiazide tablets
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
72
States / cities
Birmingham, Alabama • Green Valley, Arizona • Mesa, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 26, 2026, 4:53 AM EDT
Completed Phase 4 Interventional Results available

18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics

NCT00654745
View directory record Official record
Conditions
Type 2 Diabetes, Hypertension
Interventions
Amlodipine, amlodipine / olmesartan medoxomil combination, Hydrochlorothiazide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 80 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
21
States / cities
Los Angeles, California • Sylmar, California • Tustin, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2010 · Synced Sep 26, 2026, 4:53 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension

NCT01658657
View directory record Official record
Conditions
Hypertension, Plasma Renin Activity
Interventions
Hydrochlorothiazide, Lisinopril, Amlodipine, metoprolol, lisinopril/hydrochlorothiazide
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Sep 26, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

The SCCS Polypill Pilot Trial

NCT02278471
View directory record Official record
Conditions
Hypertension, Hyperlipidemia
Interventions
Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
45 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Sep 26, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly

NCT00368277
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Ramipril, Hydrochlorothiazide, Amlodipine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
65 Years and older
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2011 · Synced Sep 26, 2026, 4:53 AM EDT
Terminated Phase 3 Interventional Results available

Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension

NCT00170950
View directory record Official record
Conditions
Hypertension
Interventions
Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter, Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter
Drug
Lead sponsor
Novartis
Industry
Eligibility
55 Years and older
Enrollment
11,506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Sep 26, 2026, 4:53 AM EDT
Completed Not applicable Interventional Results available

Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension

NCT02412761
View directory record Official record
Conditions
Essential Hypertension
Interventions
Lisinopril, Amlodipine, Hydrochlorothiazide
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
9 Years to 22 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Sep 26, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension

NCT00667719
View directory record Official record
Conditions
Essential Hypertension
Interventions
Aliskiren, Amlodipine, Hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Sep 26, 2026, 4:53 AM EDT
Completed No phase listed Observational

Genetics of Hypertension Associated Treatments (GenHAT)

NCT00006294
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Hypertension, Coronary Disease, Myocardial Infarction
Interventions
Chlorthalidone, Lisinopril, Amlodipine, Doxazosin
Drug
Lead sponsor
Donna Arnett, 257-5678
Other
Eligibility
55 Years and older
Enrollment
37,939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Sep 26, 2026, 4:53 AM EDT
Completed Phase 3 Interventional

A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg

NCT00219115
View directory record Official record
Conditions
Hypertension
Interventions
aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Sep 26, 2026, 4:53 AM EDT
Completed Phase 4 Interventional Results available

N-of-1 Trials In Children With Hypertension

NCT03461003
View directory record Official record
Conditions
Pediatric Hypertension
Interventions
NICHE method, Usual care, Amlodipine, Lisinopril, Hydrochlorothiazide, Losartan
Other · Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
10 Years to 22 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Sep 26, 2026, 4:53 AM EDT